| Abstract |
Objective: To investigate the effects of celecoxib on inflammatory cytokine levels and psychiatric symptoms in patients with first-episode schizophrenia. Methods: 102 patients with first-episode schizophrenia who were admitted to our hospital from June 2016 to June 2018 were enrolled. The patients were divided into study group and control group according to the random number table method, 51 cases in each group. Ketone treatment, the study group was treated with celecoxib on the basis of the control group, the side reaction scale and positive and negative symptom scales were used to assess the patients side effects and psychiatric symptoms, and the patients were assessed by the positive and negative symptom scale reduction rate. The therapeutic effect was determined by enzyme-linked immunosorbent assay (ELISA) for interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-1β (interleukin-1β). , IL-1β), tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17) and γ-interferon (interferon-γ, IFN-γ) )Level.Results: The general pathological score, negative score, positive score and total score of the positive and negative symptom scales of patients treated at 4 weeks and 6 weeks were lower than the baseline, and the scores of the positive and negative symptom scales were lower than the treatment for 4 weeks. The difference was statistically significant (P<0.05). The negative and total scores of the positive and negative symptom scales in the study group were lower than those in the control group at 4 and 6 weeks of treatment, and the difference was statistically significant (P<0.05). Weeks and 6 weeks, the scores of the side effects scale of the two groups were decreased, the difference was statistically significant (P<0.05). After 6 weeks of treatment, the levels of IL-17, IFN-γ and TNF-α decreased in both groups, and The levels of IL-17, IFN-γ and TNF-α in the study group were lower than those in the control group, and the difference was statistically significant (P<0.05). With the treatment, IL-4 and IL-6 decreased in both groups, but The difference was not statistically significant (P>0.05). After treatment, the level of IL-1β in the study group was significantly lower (P<0.05). The correlation coefficient between the TNF-α level and the total score of the positive and negative symptom scales in the study group. At 0.206 (P=0.032), the study group had negative IFN-γ levels and positive and negative symptom scales. The correlation coefficient was 0.359 (P=0.010), the correlation coefficient between the TNF-α level of the control group and the total score of the positive and negative symptoms scale was 0.351 (P=0.013), and the IFN-γ level of the control group and the positive and negative symptom scales were negative. The correlation coefficient was 0.388 (P=0.006). The total effective rate of the study group was 88.23% after treatment for 6 weeks, which was 13.72% higher than that of the control group. The difference was statistically significant (χ2=2.365, P<0.05).Conclusion: Celecoxib can improve the mental symptoms of patients with first-episode schizophrenia, reduce the level of inflammatory cytokines in patients, and improve the treatment effect.
|